{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:02:44Z","timestamp":1773288164395,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jns.2021.117337","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T16:52:00Z","timestamp":1613407920000},"page":"117337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Highly sensitive screening of antisense sequences for different types of DMD mutations in patients' urine-derived cells"],"prefix":"10.1016","volume":"423","author":[{"given":"Hotake","family":"Takizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shimizu-Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Mori-Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jns.2021.117337_bb0005","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"9791","key":"10.1016\/j.jns.2021.117337_bb0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jns.2021.117337_bb0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2021.117337_bb0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.jns.2021.117337_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"437","key":"10.1016\/j.jns.2021.117337_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2021.117337_bb0035","unstructured":"FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy (drugs.com). https:\/\/www.drugs.com\/newdrugs\/fda-approves-viltepso-viltolarsen-duchenne-muscular-dystrophy-patients-amenable-exon-53-skipping-5325.html (Retrieved on January 2, 2021) 2021."},{"issue":"9","key":"10.1016\/j.jns.2021.117337_bb0040","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1089\/hum.2006.061","article-title":"Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle","volume":"18","author":"Arechavala-Gomeza","year":"2007","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.jns.2021.117337_bb0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nmd.2009.10.013","article-title":"Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials","volume":"20","author":"Popplewell","year":"2010","journal-title":"Neuromuscul. Disord. N.M.D"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2021.117337_bb0050","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0960-8966(02)00086-X","article-title":"Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy","volume":"12","author":"Aartsma-Rus","year":"2002","journal-title":"Neuromuscul. Disord. N.M.D"},{"key":"10.1016\/j.jns.2021.117337_bb0055","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","article-title":"Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells","volume":"10","author":"van Deutekom","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.jns.2021.117337_bb0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/1043034041648444","article-title":"Chimeric RNA\/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of Duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon","volume":"15","author":"Surono","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jns.2021.117337_bb0065","doi-asserted-by":"crossref","first-page":"9456","DOI":"10.1073\/pnas.142302299","article-title":"Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48\u201350 DMD cells","volume":"99","author":"De Angelis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jns.2021.117337_bb0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1474-9728.2002.00017.x","article-title":"Regenerative potential of human skeletal muscle during aging","volume":"1","author":"Renault","year":"2002","journal-title":"Aging Cell"},{"key":"10.1016\/j.jns.2021.117337_bb0075","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jns.2021.117337_bb0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","article-title":"NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy","volume":"13","author":"Watanabe","year":"2018","journal-title":"Mol. Ther. Nucl. Acids"},{"issue":"5","key":"10.1016\/j.jns.2021.117337_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050627","article-title":"Urinary stem cells as tools to study genetic disease: overview of the literature","volume":"8","author":"Falzarano","year":"2019","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.jns.2021.117337_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030573","article-title":"Urine-derived stem cells: applications in regenerative and predictive medicine","volume":"9","author":"Bento","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jns.2021.117337_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13395-016-0103-9","article-title":"Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease","volume":"6","author":"Kim","year":"2016","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.jns.2021.117337_bb0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1089\/hum.2016.079","article-title":"Duchenne muscular dystrophy myogenic cells from urine-derived stem cells recapitulate the dystrophin genotype and phenotype","volume":"27","author":"Falzarano","year":"2016","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.jns.2021.117337_bb0105","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/s41598-019-40421-z","article-title":"Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin a hydrochloride","volume":"9","author":"Takizawa","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2021.117337_bb0110","article-title":"Exon skipping in directly reprogrammed myotubes obtained from human urine-derived cells","volume":"159","author":"Takizawa","year":"2020","journal-title":"JoVE"},{"issue":"5","key":"10.1016\/j.jns.2021.117337_bb0115","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.juro.2008.07.023","article-title":"Urine derived cells are a potential source for urological tissue reconstruction","volume":"180","author":"Zhang","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.jns.2021.117337_bb0120","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jns.2021.117337_bb0125","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/nprot.2012.115","article-title":"Generation of human induced pluripotent stem cells from urine samples","volume":"7","author":"Zhou","year":"2012","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.jns.2021.117337_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0960-8966(92)90025-2","article-title":"Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients","volume":"2","author":"Fanin","year":"1992","journal-title":"Neuromuscul. Disord. N.M.D"},{"issue":"5","key":"10.1016\/j.jns.2021.117337_bb0135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nmd.2010.03.007","article-title":"Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials","volume":"20","author":"Arechavala-Gomeza","year":"2010","journal-title":"Neuromuscul. Disord. N.M.D"},{"issue":"5","key":"10.1016\/j.jns.2021.117337_bb0140","first-page":"1007","article-title":"Exon skipping and translation in patients with frameshift deletions in the dystrophin gene","volume":"53","author":"Sherratt","year":"1993","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.jns.2021.117337_bb0145","first-page":"158","article-title":"Frameshift deletions of exons 3\u20137 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production","volume":"56","author":"Winnard","year":"1995","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.jns.2021.117337_bb0150","first-page":"725","article-title":"Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin","volume":"56","author":"Thanh","year":"1995","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.jns.2021.117337_bb0155","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1083\/jcb.148.5.985","article-title":"Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion","volume":"148","author":"Lu","year":"2000","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.jns.2021.117337_bb0160","first-page":"950","article-title":"Somatic reversion\/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers","volume":"50","author":"Klein","year":"1992","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.jns.2021.117337_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069194","article-title":"Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice","volume":"8","author":"Echigoya","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:52:26Z","timestamp":1758383546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"alternative-id":["S0022510X21000307"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117337","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly sensitive screening of antisense sequences for different types of DMD mutations in patients' urine-derived cells","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117337"}}